File - In this Monday, May 17, 2010 file photo, Dr. Mansour Samadpour points out a growth of of salmonella in a petri dish at IEH Laboratories in Lake Forest Park, Wash. (AP Photo/Elaine Thompson)
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Eleven biotech companies and research teams in Britain and the United States were awarded up to $48 million in funding Thursday to speed development of new antibiotics powerful enough to take on the world's deadliest superbugs.Announcing its first funding, a new U.S.-U.K. alliance known as CARB-X, short for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, said it would invest an initial $24 million in 11 biotech companies pursing various projects to develop antibiotics and diagnostic.Drug-resistant infections kill 700,000 people a year worldwide, and the last new antibiotic class to be approved for market was discovered in 1984 .
FOLLOW THIS ARTICLE